

# Olaf H Klungel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5078967/publications.pdf>

Version: 2024-02-01

124  
papers

4,090  
citations

186265

28  
h-index

133252

59  
g-index

127  
all docs

127  
docs citations

127  
times ranked

8431  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids and crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 4-12.	3.0	34
2	Non-vitamin K antagonist oral anticoagulants, proton pump inhibitors and gastrointestinal bleeds. <i>Heart</i> , 2022, 108, 613-618.	2.9	7
3	Impact of vomiting on P2Y12 platelet inhibition in patients with ST-elevation myocardial infarction: A prespecified subanalysis of the ON-TIME 3 trial. <i>American Heart Journal</i> , 2022, 243, 39-42.	2.7	0
4	Incidence, hospitalization and mortality and their changes over time in people with a first ever diabetic foot ulcer. <i>Diabetic Medicine</i> , 2022, 39, e14725.	2.3	10
5	Pre-approval and post-approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 2169-2179.	2.4	5
6	Challenges in the Design, Registration, and Reporting of Noninferiority Trials. <i>JAMA Psychiatry</i> , 2022, 79, 191.	11.0	1
7	The neurological safety of covid-19 vaccines. <i>BMJ</i> , 2022, 376, o522.	6.0	1
8	Oral anticoagulants in patients with atrial fibrillation at low stroke risk: a multicentre observational study. <i>European Heart Journal</i> , 2022, 43, 3528-3538.	2.2	22
9	Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors. <i>Cancer Epidemiology</i> , 2022, 78, 102149.	1.9	3
10	Mapping the risk of infections in patients with multiple sclerosis: A multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1808-1818.	3.0	3
11	Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f72-f80.	3.0	37
12	Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 988-1000.	2.4	19
13	Prescribers' compliance with summary of product characteristics of dabigatran, rivaroxaban and apixaban – A European comparative drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 440-454.	2.5	3
14	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 445-450.	1.9	3
15	Association of preceding antithrombotic therapy in atrial fibrillation patients with ischaemic stroke, intracranial haemorrhage, or gastrointestinal bleed and mortality. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 3-10.	3.0	15
16	Estimation of manufacturing development costs of cell-based therapies: a feasibility study. <i>Cytotherapy</i> , 2021, 23, 730-739.	0.7	12
17	Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. <i>Scientific Reports</i> , 2021, 11, 2794.	3.3	0
18	Use of Sodium-Glucose Co-Transporter-2-Inhibitors (SGLT2-Is) and Risk of Lower Limb Amputation. <i>Current Drug Safety</i> , 2021, 16, 62-72.	0.6	8

#	ARTICLE	IF	CITATIONS
19	Greedy caliper propensity score matching can yield variable estimates of the treatmentâ€œoutcome associationâ€œ”A simulation study. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 934-951.	1.9	9
20	Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands. <i>Scientific Reports</i> , 2021, 11, 6306.	3.3	48
21	Response to: Kumar N, Ahmed M. Letter to the editor in response to Komen et al. 2021. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, e31-e31.	3.0	1
22	Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3508-3517.	2.4	1
23	A systematic review of how missing data are handled and reported in <scp>multiâ€œdatabase</scp> pharmacoepidemiologic studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 819-826.	1.9	10
24	Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. <i>Clinical and Translational Science</i> , 2021, 14, 1566-1577.	3.1	10
25	Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries. <i>Europace</i> , 2021, 23, 1722-1730.	1.7	24
26	Global covid-19 vaccine rollout and safety surveillanceâ€œ”how to keep pace. <i>BMJ, The</i> , 2021, 373, n1416.	6.0	17
27	Determinants of treatment modification before and after implementation of the updated 2015 NICE guideline on type 2 diabetes: A retrospective cohort study. <i>Diabetes Research and Clinical Practice</i> , 2021, 176, 108828.	2.8	0
28	Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle â€œ a focus on benefits and risks. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	2.4	3
29	Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple populationâ€œbased cohort studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1339-1352.	1.9	17
30	Thiazolidinediones and Glucagonâ€œLike Peptideâ€œ1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Hepatology</i> , 2021, 74, 2467-2477.	7.3	10
31	Strengthening international surveillance of vaccine safety. <i>BMJ, The</i> , 2021, 374, n1994.	6.0	7
32	Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1703-1715.	1.9	11
33	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 3-7.	1.9	28
34	Managing Uncertainties Due to Limited Evidence in Economic Evaluations of Novel Anti-Tuberculosis Regimens: A Systematic Review. <i>PharmacoEconomics - Open</i> , 2020, 4, 223-233.	1.8	1
35	Concomitant Anticoagulant and Antidepressant Therapy in Atrial Fibrillation Patients and Risk of Stroke and Bleeding. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 287-294.	4.7	10
36	Affordability of oncology drugs: accuracy of budget impact estimations. <i>Journal of Market Access &amp; Health Policy</i> , 2020, 8, 1697558.	1.5	1

#	ARTICLE	IF	CITATIONS
37	Effect of CYP3A4*22 and PPAR- $\alpha$ Genetic Variants on Platelet Reactivity in Patients Treated with Clopidogrel and Lipid-Lowering Drugs Undergoing Elective Percutaneous Coronary Intervention. <i>Genes</i> , 2020, 11, 1068.	2.4	2
38	What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings. <i>Cytotherapy</i> , 2020, 22, 388-397.	0.7	29
39	Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. <i>Clinical Therapeutics</i> , 2020, 42, 1588-1594.	2.5	3
40	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
41	Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1263-1272.	1.9	2
42	A Review of Methodological Considerations for Economic Evaluations of Gene Therapies and Their Application in Literature. <i>Value in Health</i> , 2020, 23, 1268-1280.	0.3	14
43	Considerations for pharmacoepidemiological analyses in the <scp>SARS-CoV-2</scp> pandemic. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 825-831.	1.9	36
44	Quality of reporting of drug exposure in pharmacoepidemiological studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1141-1150.	1.9	4
45	Application of Healthcare "Big Data"™ in CNS Drug Research: The Example of the Neurological and mental health Global Epidemiology Network (NeuroGEN). <i>CNS Drugs</i> , 2020, 34, 897-913.	5.9	14
46	A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics. <i>European Journal of Health Economics</i> , 2020, 21, 845-853.	2.8	1
47	Development and Regulation of Gene and Cell-Based Therapies in Europe: A Quantification and Reflection. <i>Trends in Pharmacological Sciences</i> , 2020, 41, 67-71.	8.7	5
48	Increasing the information provided by probabilistic sensitivity analysis: The relative density plot. <i>Cost Effectiveness and Resource Allocation</i> , 2020, 18, 54.	1.5	2
49	The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs. <i>International Journal of Health Policy and Management</i> , 2020, , .	0.9	8
50	Postauthorization Changes to Specific Obligations of Conditionally Authorized Medicines in the European Union: A Retrospective Cohort Study. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 426-435.	4.7	12
51	Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study. <i>Europace</i> , 2019, 21, 99-105.	1.7	1
52	Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1563-1571.	1.9	2
53	Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1355-1362.	4.5	27
54	Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 2524-2539.	2.4	41

#	ARTICLE	IF	CITATIONS
55	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) –EMA Joint Big Data Task Force. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 1640-1641.	1.9	2
56	Impact of the definition of osteoarthritis and of the timing of its onset on the association between type 2 diabetes mellitus and osteoarthritis: Clinical Practice Research Datalink. <i>Diabetes Research and Clinical Practice</i> , 2019, 148, 240-248.	2.8	2
57	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	3.6	17
58	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	3.6	22
59	Cyclooxygenase selectivity and chemical groups of nonsteroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/noncase study in Vigibase. <i>Fundamental and Clinical Pharmacology</i> , 2019, 33, 589-600.	1.9	5
60	Conditional Financing of Drugs in the Netherlands: Past, Present, and Future—Results From Stakeholder Interviews. <i>Value in Health</i> , 2019, 22, 399-407.	0.3	12
61	Risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 623-631.	1.5	7
62	Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study. <i>European Journal of Health Economics</i> , 2019, 20, 857-867.	2.8	8
63	Real-world treatment patterns and outcomes of patients with extensive disease small cell lung cancer (ED SCLC)., 2019, , .		0
64	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in extensive disease small cell lung cancer (ED SCLC)., 2019, , .		1
65	Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: A population-based cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1056-1060.	4.4	8
66	Medications Recommended for Secondary Prevention After First Acute Coronary Syndrome: Effectiveness of Treatment Combinations in a Real-Life Setting. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 1038-1046.	4.7	6
67	Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. <i>Pharmacoeconomics</i> , 2018, 36, 359-368.	3.3	67
68	Patients' beliefs about medicine are associated with early thiopurine discontinuation in patients with inflammatory bowel diseases. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 167-173.	1.6	10
69	The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). <i>BMJ: British Medical Journal</i> , 2018, 363, k3532.	2.3	268
70	Challenges in Advanced Therapy Medicinal Product Development: A Survey among Companies in Europe. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 11, 121-130.	4.1	63
71	Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: a feasibility study. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 222.	2.4	13
72	Systematic evaluation of the efficacy-effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer. <i>European Respiratory Journal</i> , 2018, 52, 1801100.	6.7	34

#	ARTICLE	IF	CITATIONS
73	Pharmacoepidemiological Approaches for Population-Based Hypothesis Testing. <i>Methods in Pharmacology and Toxicology</i> , 2018, , 201-216.	0.2	0
74	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. <i>Drug and Alcohol Dependence</i> , 2018, 188, 94-101.	3.2	10
75	Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review. <i>PLoS ONE</i> , 2018, 13, e0193293.	2.5	3
76	Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. <i>Journal of Clinical Epidemiology</i> , 2018, 104, 15-23.	5.0	4
77	Pattern of risks of rheumatoid arthritis among patients using statins: A cohort study with the clinical practice research datalink. <i>PLoS ONE</i> , 2018, 13, e0193297.	2.5	14
78	Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 285-293.	1.9	18
79	Defining the noninferiority margin and analysing noninferiority: An overview. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1636-1642.	2.4	113
80	Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1141-1148.	1.9	23
81	Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. <i>Trials</i> , 2017, 18, 107.	1.6	56
82	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Value in Health</i> , 2017, 20, 1009-1022.	0.3	70
83	Reporting to Improve Reproducibility and Facilitate Validity Assessment for Healthcare Database Studies V1.0. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1018-1032.	1.9	126
84	More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1873-1881.	1.9	23
85	The impact of serum potassiumâ€“influencing antihypertensive drugs on the risk of outâ€“ofâ€“hospital cardiac arrest: A caseâ€“control study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2541-2548.	2.4	8
86	The impact of age and sex on the reporting of cough and angioedema with reninâ€“angiotensin system inhibitors: a case/noncase study in VigiBase. <i>Fundamental and Clinical Pharmacology</i> , 2017, 31, 676-684.	1.9	25
87	Pattern of risks of systemic lupus erythematosus among statin users: a population-based cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1723-1730.	0.9	13
88	Patterns of antiplatelet drug use after a first myocardial infarction during a 10â€“year period. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 632-641.	2.4	7
89	Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 175-184.	1.3	52
90	Caseâ€“only designs for studying the association of antidepressants and hip or femur fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 103-113.	1.9	11

#	ARTICLE	IF	CITATIONS
91	Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 714-23.	2.1	40
92	Understanding inconsistency in the results from observational pharmacoepidemiological studies: the case of antidepressant use and risk of hip/femur fractures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 88-102.	1.9	23
93	Instrumental variables analysis using multiple databases: an example of antidepressant use and risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 122-131.	1.9	6
94	Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 79-87.	1.9	12
95	Exposure to benzodiazepines (anxiolytics, hypnotics and related drugs) in seven European electronic healthcare databases: a cross-national descriptive study from the PROTECT-EU Project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 56-65.	1.9	96
96	Prevalence of antibiotic use: a comparison across various European health care data sources. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 11-20.	1.9	46
97	The risk of acute liver injury among users of antibiotic medications: a comparison of case-only studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 39-46.	1.9	7
98	Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: a study of inhaled long-acting beta <sub>2</sub> -agonist use and the risk of myocardial infarction. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 132-141.	1.9	11
99	Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 29-38.	1.9	16
100	Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 114-121.	1.9	24
101	Impact of varying outcomes and definitions of suicidality on the associations of antiepileptic drugs and suicidality: comparisons from UK Clinical Practice Research Datalink (CPRD) and Danish national registries (DNR). <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 142-155.	1.9	12
102	The IMI PROTECT project: purpose, organizational structure, and procedures. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 5-10.	1.9	20
103	Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 156-165.	1.9	36
104	Best (but oft-forgotten) practices: propensity score methods in clinical nutrition research. <i>American Journal of Clinical Nutrition</i> , 2016, 104, 247-258.	4.7	42
105	Unmeasured confounding in pharmacoepidemiology. <i>Annals of Epidemiology</i> , 2016, 26, 85-86.	1.9	8
106	Risk patterns in drug safety study using relative times by accelerated failure time models when proportional hazards assumption is questionable: an illustrative case study of cancer risk of patients on glucose-lowering therapies. <i>Pharmaceutical Statistics</i> , 2015, 14, 382-394.	1.3	6
107	Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: a systematic review. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 122-131.	5.0	221
108	Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. <i>Annals of Epidemiology</i> , 2015, 25, 590-596.	1.9	15

#	ARTICLE	IF	CITATIONS
109	Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. <i>Journal of Clinical Epidemiology</i> , 2015, 68, 387-396.	5.0	4
110	Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1851-1859.	2.8	162
111	HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. <i>Lancet, The</i> , 2015, 385, 351-361.	13.7	562
112	Time Trends of Period Prevalence Rates of Patients with Inhaled Long-Acting Beta-2-Agonists-Containing Prescriptions: A European Comparative Database Study. <i>PLoS ONE</i> , 2015, 10, e0117628.	2.5	11
113	Utilisation and Off-Label Prescriptions of Respiratory Drugs in Children. <i>PLoS ONE</i> , 2014, 9, e105110.	2.5	10
114	Giant Cell Arteritis and Polymyalgia Rheumatica After Reexposure to a Statin: A Case Report. <i>Annals of Internal Medicine</i> , 2014, 161, 614.	3.9	11
115	Antiepileptic drug use in seven electronic health record databases in Europe: A methodologic comparison. <i>Epilepsia</i> , 2014, 55, 666-673.	5.1	35
116	Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. <i>BMJ, The</i> , 2014, 349, g4164-g4164.	6.0	528
117	Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: results from a systematic review and simulation study. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 821-829.	5.0	44
118	Justification of exclusion criteria was underreported in a review of cardiovascular trials. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 635-644.	5.0	23
119	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	2.8	115
120	Statins accelerate the onset of collagen type II-induced arthritis in mice. <i>Arthritis Research and Therapy</i> , 2012, 14, R90.	3.5	20
121	Statin-Associated Polymyalgia Rheumatica. An Analysis Using WHO Global Individual Case Safety Database: A Case/Non-Case Approach. <i>PLoS ONE</i> , 2012, 7, e41289.	2.5	27
122	Association Between Statin Use and Lupus-Like Syndrome Using Spontaneous Reports. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 373-381.	3.4	28
123	Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake Inhibitors and Coumarins. <i>Archives of Internal Medicine</i> , 2008, 168, 180.	3.8	127
124	Sex differences in the medication choice for hypertension in general practice. A study with written case simulations. <i>International Journal of Clinical Pharmacy</i> , 2000, 22, 140-146.	1.4	5